Abstract
P134 MK-5684-003: A randomized, phase 3 study of CYP11A1 inhibitor ppevesostat (MK- 5684) versus Next-Generation Hormonal Agent (NHA) switch in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) after NHA and taxane-based chemotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
